TP53 and neoplasm: SPA had molecular features including significantly higher tumor mutation burden (TMB), the higher frequency of TP53 mutation together with EGFR/TP53 co-mutation, and higher immuno-resistant microenvironment, that indicates a poor response to chemotherapy, such as tyrosine kinase inhibitors (TKIs).